TVTX

17.39

1.86% -0.33

Handel nachbörslich: 17.51 0.12 +0.69%

Travere Therapeutics Inc (TVTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TVTX? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$17.72

Offen:

$17.69

24-Stunden-Volumen:

1.14M

Relative Volume:

0.63

Marktkapitalisierung:

$1.51B

Einnahmen:

$203.45M

Nettoeinkommen (Verlust:

$-351.45M

KGV:

-3.8473

EPS:

-4.52

Netto-Cashflow:

$-369.41M

1W Leistung:

-8.62%

1M Leistung:

-2.69%

6M Leistung:

+186.96%

1J Leistung:

+197.26%

1-Tages-Spanne:

$16.86

$17.86

1-Wochen-Bereich:

$16.86

$19.51

52-Wochen-Spanne:

$5.12

$20.33

Travere Therapeutics Inc Stock (TVTX) Company Profile

Firmenname

Travere Therapeutics Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

888-969-7879

Adresse

3611 VALLEY CENTRE DR, SAN DIEGO

Mitarbeiter

380

Twitter

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

TVTX's Discussions on Twitter

Vergleichen Sie TVTX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TVTX	17.39	1.51B	203.45M	-351.45M	-369.41M	-4.52
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-03-27	Herabstufung	Guggenheim	Buy → Neutral
2023-12-05	Hochstufung	Citigroup	Neutral → Buy
2023-11-20	Eingeleitet	Citigroup	Neutral
2023-09-22	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-09-21	Herabstufung	William Blair	Outperform → Mkt Perform
2023-09-06	Fortgesetzt	Evercore ISI	Outperform
2023-07-21	Eingeleitet	JP Morgan	Overweight
2023-06-07	Fortgesetzt	Piper Sandler	Neutral
2023-05-22	Eingeleitet	TD Cowen	Outperform
2023-05-05	Hochstufung	Bryan Garnier	Sell → Neutral
2023-03-01	Eingeleitet	Guggenheim	Buy
2023-02-21	Hochstufung	Wedbush	Neutral → Outperform
2022-12-14	Eingeleitet	Stifel	Hold
2022-12-05	Eingeleitet	Wells Fargo	Overweight
2022-09-21	Eingeleitet	Bryan Garnier	Sell
2022-07-14	Fortgesetzt	Canaccord Genuity	Buy
2022-03-31	Eingeleitet	Piper Sandler	Overweight
2022-02-28	Eingeleitet	H.C. Wainwright	Buy
2021-05-26	Herabstufung	Wedbush	Outperform → Neutral

Alle ansehen

Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten

03:46 AM

Los Angeles Capital Management LLC Sells 56,866 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

03:46 AM

Nov 15, 2024

When (TVTX) Moves Investors should Listen - Stock Traders Daily

Nov 15, 2024

Exploring Three High Growth Tech Stocks in the United States - Simply Wall St

Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires Significant Stake in Travere The - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Woodline Partners LP Expands Stake in Travere Therapeutics Inc - GuruFocus.com

Nov 14, 2024

Deep Track Capital, LP Reduces Stake in Travere Therapeutics Inc - GuruFocus.com

Nov 14, 2024

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 - MarketBeat

Nov 14, 2024

Nov 13, 2024

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Nov 13, 2024

Travere Therapeutics Awards 24,400 RSUs to New Employees in Talent Acquisition Push | TVTX Stock News - StockTitan

Nov 13, 2024

Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - The Globe and Mail

Nov 13, 2024

Travere Therapeutics Completes $143.8 Million Public Offering - Marketscreener.com

Nov 13, 2024

Nov 12, 2024

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - The Manila Times

Nov 12, 2024

Nov 11, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Nov 10, 2024

Nov 09, 2024

Travere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month HighHere's What Happened - MarketBeat

Nov 09, 2024

Nov 08, 2024

TVTX stock soars to 52-week high, hits $19.29 amid robust gains - Investing.com India

Nov 08, 2024

Latham & Watkins Advises on Travere Therapeutics’ Public Offering of Common Stock - Latham & Watkins LLP

Nov 08, 2024

Travere Therapeutics plans public stock offering By Investing.com - Investing.com Australia

Nov 08, 2024

Nov 07, 2024

Travere Therapeutics Announces Pricing of Public Offering of Common Stock - The Manila Times

Nov 07, 2024

Travere Therapeutics Announces Pricing of Public Offering of Common Stock - Benzinga

Nov 07, 2024

Travere Therapeutics plans public stock offering - Investing.com India

Nov 07, 2024

Travere Therapeutics Launches Public Stock Offering, Led by Jefferies & Leerink | TVTX Stock News - StockTitan

Nov 07, 2024

Nov 05, 2024

Travere Therapeutics' SWOT analysis: filspari approval boosts rare disease stock outlook - Investing.com UK

Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com

Nov 05, 2024

Nov 04, 2024

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 04, 2024

Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Nov 04, 2024

Nov 03, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat

Nov 03, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World

Nov 03, 2024

Nov 01, 2024

TVTXTravere Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024

Scotiabank Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat

Nov 01, 2024

Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia

Nov 01, 2024

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 01, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024